Breast Cancer Clinical Trial

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

Summary

Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy adult male and female participants (drug-drug interaction study). The study drug BAY1817080 is a new drug under development with a goal to suppress pain and chronic cough. It works by binding to and blocking proteins related to pain in the body. Rosuvastatin is an approved and marketed drug to lower high levels of "bad" cholesterol (a waxy, fat-like substance found in blood). Both drugs interact with the same proteins (molecules) in the human body, and as a result, the study drug may affect the way rosuvastatin is taken up and used by the body when applied together.

Participants in this study will be asked to visit the clinic 3 times over a period of 3 to 4 weeks. Each participant will receive rosuvastatin tablets twice with at least 11 days in between and the study drug tablets twice daily for 14 days. Blood samples will be taken from the participants to measure the blood levels of rosuvastatin.

View Full Description

Full Description

The primary objective of the study is to investigate the influence of multiple doses of BAY1817080 on the pharmacokinetics of rosuvastatin given concomitantly. Secondary objective is to investigate the safety of BAY1817080.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant is healthy as determined by the investigator
White or Black race
Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m² at screening
Body weight of at least 50 kg at screening

Exclusion Criteria:

Known or suspected allergy or hypersensitivity to BAY1817080, rosuvastatin or any of their excipients
Asian race
Contraindications to rosuvastatin
Any use of systemic or topically active medication or herbal remedies, prescription or non-prescription, within 1 week prior to the first study intervention administration or during the study until follow-up (occasional use of ibuprofen is permissible)
History of or positive COVID-19 test or contact with COVID-19 positive subject in past 4 weeks

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

14

Study ID:

NCT04252300

Recruitment Status:

Completed

Sponsor:

Bayer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Covance Clinical Research Unit, Inc.
Daytona Beach Florida, 32117, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

14

Study ID:

NCT04252300

Recruitment Status:

Completed

Sponsor:


Bayer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider